Medigus (NASDAQ:MDGS) Trading Down 1.5%

Medigus Ltd. (NASDAQ:MDGSGet Rating)’s stock price fell 1.5% during mid-day trading on Monday . The stock traded as low as $4.56 and last traded at $4.60. 6,081 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 14,158 shares. The stock had previously closed at $4.67.

Medigus Stock Performance

The company has a quick ratio of 1.33, a current ratio of 1.39 and a debt-to-equity ratio of 0.11. The firm has a fifty day simple moving average of $4.84 and a 200-day simple moving average of $6.55.

Medigus Announces Dividend

The firm also recently declared a dividend, which was paid on Wednesday, December 28th. Investors of record on Tuesday, December 20th were given a dividend of $0.85 per share. This represents a dividend yield of 12.9%. The ex-dividend date of this dividend was Monday, December 19th.

Hedge Funds Weigh In On Medigus

A hedge fund recently bought a new stake in Medigus stock. Virtu Financial LLC acquired a new stake in shares of Medigus Ltd. (NASDAQ:MDGSGet Rating) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 61,809 shares of the company’s stock, valued at approximately $40,000. Virtu Financial LLC owned 0.39% of Medigus as of its most recent filing with the Securities and Exchange Commission (SEC). 9.18% of the stock is currently owned by institutional investors and hedge funds.

About Medigus

(Get Rating)

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities.

See Also

Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with's FREE daily email newsletter.